Biotech has become a data business – and AI is the intelligence layer that makes that data economically powerful.

Over the last decade, biotechnology and life sciences have generated an unprecedented volume of data: whole-genome sequences, longitudinal electronic health records, high‑content microscopy, proteomics, single‑cell readouts and real‑world evidence from millions of patients. At the same time, advances in computing hardware and machine learning have made it feasible to train models on these massive datasets at scale. Analyst estimates now put the global AI market well above the hundreds of billions of US dollars, with forecasts into the trillions over the coming decade, and healthcare is consistently highlighted as one of the most important growth verticals.¹

Within pharmaceutical and biotechnology companies specifically, the AI market is still small relative to total R&D spend but is expanding rapidly – from roughly low‑single‑digit billions of dollars today to a projected mid‑teens of billions by the mid‑2030s, driven by demand for faster, cheaper and more predictable drug development.² This is not just a technology story; it is a structural shift in how biological innovation is financed, governed and commercialized.

Several forces are accelerating the convergence of AI and biotech:

• Data abundance: Next‑generation sequencing, high‑throughput screening and large‑scale imaging have turned previously scarce biological measurements into rich, multi‑modal datasets.
• Algorithmic maturity: Deep learning, transformer architectures and generative models that proved themselves in language and vision now power protein structure prediction, molecular design and clinical prediction tasks.
• Falling compute costs: Cloud infrastructure and specialized hardware have made it economically viable to train large models on terabytes of biological and clinical data.
• Regulatory traction: Hundreds of AI‑enabled medical devices and algorithms have already passed regulatory review in major markets, especially in imaging, giving regulators and clinicians familiarity with the technology.³
• Capital and partnerships: Venture capital, corporate venture arms and big pharma licensing deals have poured billions of dollars into AI‑first biotech platforms over just a few years, rapidly professionalizing the ecosystem.⁴

For executives and investors, the key takeaway is clear: AI is not an optional add‑on to biotech. It is steadily becoming a core capability that will differentiate winners from laggards across discovery, development, manufacturing and commercialization.

Where AI is already reshaping biotech

AI is not a theoretical promise in biotechnology; it is already embedded in high‑value workflows. The most advanced use cases today cluster around four domains: drug discovery and development, genomics and precision medicine, diagnostics and digital biomarkers, and synthetic biology plus lab automation.

AI‑accelerated drug discovery and development

Drug discovery has traditionally been slow, risky and expensive. AI is changing that by compressing search spaces and highlighting the most promising paths earlier in the pipeline. Platforms from companies such as Exscientia, Insilico Medicine, BenevolentAI and XtalPi use deep learning and physics‑informed models to perform virtual screening, optimize molecular structures and prioritize targets based on massive biological knowledge graphs and experimental feedback.

These AI platforms can:

• Search billions of potential small‑molecule structures in silico and generate novel candidates that satisfy multiple constraints (potency, selectivity, ADME, developability).
• Predict on‑ and off‑target activity, toxicity and pharmacokinetic profiles before synthesis, reducing wasted chemistry cycles.
• Identify new indications and reposition existing molecules by analysing polypharmacology across the proteome.
• Help design more efficient, better‑powered clinical trials by simulating likely outcomes and identifying responder sub‑populations.

The pipeline impact is visible. One of Exscientia’s small‑molecule candidates was among the first AI‑designed drugs to enter human trials, and the company continues to advance multiple AI‑generated programs in oncology and immunology. At the same time, Insilico Medicine has taken AI‑identified targets through to clinical‑stage assets, and has demonstrated a fully automated “AI + robotics” discovery loop in its intelligent laboratories.⁵

On the big‑pharma side, companies such as AstraZeneca, GSK, Novartis, Sanofi, Pfizer and Roche have signed multi‑year collaborations with AI platforms to co‑discover targets and share economics on downstream assets. Some of these deals are structured with potential milestone payments in the billions of dollars, underlining how strategically important AI‑enabled discovery has become for pipelines under patent‑cliff pressure.

Genomics and precision medicine

High‑throughput sequencing has made it possible to read whole genomes, exomes and transcriptomes at population scale. The challenge is to interpret what all of those variants, expression patterns and epigenetic marks actually mean for disease risk and treatment. Here, AI excels at pattern recognition across very high‑dimensional data.

Companies such as Deep Genomics, Tempus and BioNTech combine AI with genomics, clinical records and other data to:

• Identify pathogenic variants and gene–disease relationships that are not obvious from traditional statistical analyses.
• Design RNA‑based or mRNA‑based therapies tailored to specific mutations and patient sub‑populations.
• Guide oncologists and other specialists toward the most effective therapies based on tumor genomics and prior treatment outcomes.

In oncology, for example, Tempus has built one of the world’s largest libraries of molecular and clinical data, and uses AI to power precision‑medicine reports, treatment recommendations and trial‑matching for cancer patients. In parallel, BioNTech is applying AI and deep genomics to personalize immunotherapies and optimize next‑generation mRNA vaccine constructs.

Diagnostics and digital biomarkers

Diagnostic workflows are being transformed by computer vision and predictive analytics. Medical imaging – radiology, cardiology, pathology and ophthalmology – is the most mature area: studies show that hundreds of AI/ML‑enabled devices and algorithms have cleared regulatory review in the US alone, the majority focused on radiology and imaging‑driven diagnosis.³

A good example is Qure.ai, a Mumbai‑based health‑tech company whose deep‑learning models interpret chest X‑rays and CT scans for conditions ranging from tuberculosis to stroke, and are deployed across dozens of countries in both public and private healthcare systems.⁷ In India, HealthCube integrates point‑of‑care diagnostics with AI‑driven decision support for frontline clinicians, bringing lab‑grade testing to resource‑constrained settings.

Beyond imaging, startups such as NIRAMAI (thermal‑imaging breast cancer screening) and SigTuple (AI‑supported microscopy for blood and urine analysis) are turning raw sensor streams into digital biomarkers that can flag disease early, triage cases and support remote diagnostics. In the pathology space, PathAI works with biopharma companies and clinical labs to use AI‑enhanced histology for more accurate diagnosis and better patient stratification in trials.

Synthetic biology and intelligent automation

Synthetic biology aims to engineer biological systems – cells, pathways, enzymes – in a predictable way. The design space is vast: countless possible gene edits, promoters, regulatory elements and protein designs. AI is becoming the design engine that explores this space efficiently.

In protein engineering, for instance, deep‑learning models and generative networks can propose novel protein sequences with desired properties. Antibody design companies such as Helixon / Earendil Bio and AI‑chemistry platforms like XtalPi apply these techniques to discover biologics and small molecules, often in close partnership with global pharma players.

Automation takes this to another level. Insilico Medicine, for example, has built an intelligent robotics lab that can design, execute and analyse many stages of the discovery workflow – from target validation and high‑throughput screening to cell‑based assays and sequencing – with minimal human intervention. Closed‑loop systems like these continuously generate new data to retrain models, making discovery more like an iterative software development process than traditional trial‑and‑error bench science.

Similar approaches are emerging in agricultural biotech and industrial biotechnology, where companies such as Bayer and others use AI to optimize crop traits, biologicals and enzyme systems for sustainable production.

Business impact, capital flows and competitive dynamics

The economic significance of AI in biotech can be viewed through three lenses: productivity gains across the value chain, flows of private and strategic capital, and the emerging competitive structure of the industry.

Productivity and economics

Drug R&D remains one of the most capital‑intensive innovation processes in the world. Industry‑wide, success rates from target idea to approved medicine remain well below 10%, and timelines often exceed a decade. AI targets that pain directly by:

• Reducing the number of dead‑end projects that enter expensive preclinical and clinical stages.
• Improving the quality of candidate selection at each stage, increasing the probability of technical and regulatory success.
• Automating routine tasks (e.g. image annotation, structure‑activity modelling, protocol optimization), freeing scarce scientific talent for higher‑value work.
• Enabling “virtual experiments” and in‑silico trials that can inform go/no‑go decisions before capital is committed at scale.

Market research focused specifically on AI in pharma and biotech suggests high‑teens compound annual growth over the next decade, from a market size of roughly US$1.8 billion in the early‑2020s to over US$13 billion by the mid‑2030s, as more companies industrialize AI across pipelines rather than in isolated pilots.² If even a fraction of anticipated efficiency gains materialize at scale, the impact on R&D productivity, asset valuations and time‑to‑market will be profound.

Venture capital and growth equity

Investor enthusiasm has already translated into substantial funding. Recent analyses indicate that AI‑enabled biopharma and healthcare companies attract a rapidly rising share of venture dollars; in some years, roughly one in four healthcare VC dollars globally has flowed into companies that put AI at the centre of their value proposition.⁴ In the United States alone, investment in AI‑driven biopharma companies reached well over US$5 billion in 2024 – roughly three times the prior year – with mega‑rounds increasingly common for later‑stage platforms that have advanced multiple assets into the clinic.⁸

Importantly, investor sentiment has shifted from “AI at any price” toward a “show‑me” stance. Capital is concentrating in platforms that can demonstrate real‑world traction: validated targets, clinical‑stage programs, revenue‑generating partnerships with large pharma or payers, and robust proprietary datasets that are difficult to replicate.

Strategic partnerships and M&A

Strategic alliances between AI‑first biotechs and established pharmaceutical companies are now a defining feature of the landscape. Partnerships like the collaboration between BenevolentAI and AstraZeneca on kidney and lung disease targets, or the series of deals between XtalPi and partners such as Pfizer and Eli Lilly, show how pharma is embedding external AI capabilities into core pipelines.

Large licensing and co‑development deals with Chinese AI‑driven drug discovery companies – including multi‑billion‑dollar arrangements between AstraZeneca and CSPC Pharmaceutical Group, and between Sanofi and Helixon / Earendil Bio – underline how AI has become a global competitive battleground for pipeline assets and platform technologies.

M&A has followed. A headline example is BioNTech’s acquisition of AI company InstaDeep, aimed at integrating AI across cancer immunotherapy and vaccine R&D. In another case, Recursion acquired digital chemistry companies Cyclica and Valence Labs to deepen its AI‑driven discovery stack and expand the scope of its “operating system for biology.”⁹

Global landscape: US, Europe, China, India and beyond

Although AI in biotech is a global phenomenon, regional ecosystems have distinct strengths and strategic positions.

United States and Europe: deep ecosystems and capital

The US and leading European markets remain the densest clusters of AI‑enabled biotech. They combine world‑class academic research, established biotech clusters, deep capital markets and the headquarters of many top pharmaceutical companies, including Pfizer, Roche, Novartis, GSK, Sanofi and Bayer.

Many of the best‑known AI‑first drug discovery platforms – such as Exscientia, Insilico Medicine, BenevolentAI, Deep Genomics, Recursion, Tempus and PathAI – are headquartered or have major operations in these regions. Regulatory agencies such as the US Food and Drug Administration and the European Medicines Agency are also actively developing guidance around AI‑enabled products, which helps give investors and innovators more predictability.

China: scale, data and industrial integration

China has emerged as a powerful player in AI‑driven biotech, supported by state‑level AI strategies, large domestic health datasets and strong integration between software, hardware and manufacturing. Chinese AI‑biotech companies, including XtalPi and several newer platforms, have signed major licensing deals with Western pharma, sometimes worth several billion dollars in potential milestones.

The country’s national health‑insurance infrastructure and rapidly expanding hospital networks generate enormous volumes of clinical data that can, under appropriate privacy regimes, be used to train AI models. Combined with competitive costs for scientific and engineering talent, this positions Chinese AI‑biotech firms as increasingly attractive partners – and potential competitors – for global incumbents.

India: cost‑effective innovation and health‑system impact

India is building a distinctive role at the intersection of AI, biotech and healthcare delivery. The country’s strengths in software engineering and IT services are now intersecting with a fast‑growing life‑sciences and med‑tech startup ecosystem. Companies such as Bugworks Research, Qure.ai, HealthCube, NIRAMAI and SigTuple illustrate how AI can be used to tackle antimicrobial resistance, cancer screening and diagnostic access both in India and globally.

Many Indian AI‑health companies focus deliberately on affordability and portability, making them natural partners for governments, NGOs and health systems in other emerging markets. As India continues to invest in digital public infrastructure and genomics initiatives, its role in AI‑biotech is likely to grow.

Rest of world

Canada, Israel, Singapore, the UK, the Nordic countries and parts of the Middle East are also building strong AI‑biotech clusters, often anchored by leading universities and national innovation programs. For globally minded investors and corporates, this means the opportunity set is geographically diverse – and so is the competition for talent, assets and partnerships.

What comes next for AI‑driven biotech

Looking ahead over the next decade, AI is likely to move from “tool” to deeply embedded infrastructure across the entire biotech value chain. Several shifts are particularly important for strategic planning.

From point solutions to end‑to‑end AI operating systems

Today’s landscape still features many point solutions: a model for image analysis here, a platform for small‑molecule design there. The trend is toward integrated operating systems for biology – platforms that stitch together target discovery, molecular design, in‑silico profiling, lab automation, data management and clinical analytics into a single, learning system. Players such as Recursion, Insilico Medicine, Deep Genomics and others are already moving in this direction.

Multimodal and “virtual cell” models

A key research frontier is multimodal AI – models that jointly learn from genomic, transcriptomic, proteomic, imaging and clinical data to build richer representations of disease biology.¹ Concepts such as “virtual cells” or “digital twins” for patients aim to simulate how a biological system will respond to interventions before they are tested in vivo. Over time, these models could help design better combination therapies, predict resistance mechanisms and individualize dosing in a way that is difficult to achieve with traditional statistical methods alone.

Clinical decision support and personalized care

In parallel, AI is moving closer to the point of care. As health systems adopt electronic records, connect diagnostics and deploy clinical decision support tools, there is large potential for AI to:

• Identify patients at high risk of disease earlier, enabling preventive interventions.
• Recommend personalized therapy options based on molecular profiles and real‑world outcomes data.
• Support clinicians with summarization, documentation and triage tasks, freeing time for relationship‑based care.

For AI‑enabled biotech companies, this opens opportunities beyond therapeutics: companion diagnostics, digital therapeutics, outcome‑based contracts and integrated care pathways where drugs, diagnostics and software are tightly linked.

New business models and competitive moats

As AI becomes standard, competitive advantage will hinge less on “having AI” and more on how it is deployed: the quality and uniqueness of proprietary data; the tightness of integration between algorithms, wet labs and clinical operations; and the ability to execute partnerships and regulatory strategies effectively. Expect to see:

• AI‑native biopharma companies that own full pipelines from discovery to commercialization.
• Platform companies that primarily monetize through partnerships, licensing and data services.
• Traditional pharmas that successfully re‑platform R&D around AI and automation, closing the gap with startups.

For all of these players, governance, trust and responsible innovation will be just as important as technical sophistication – a theme explored next.

Risk, ethics and governance priorities

The upside of AI in biotech is enormous, but so are the responsibilities. Boards and executive teams should pay particular attention to five categories of risk and governance.

1. Data quality, representativeness and privacy

AI is only as good as the data it learns from. Many biomedical datasets are noisy, fragmented or skewed toward certain populations. If models are trained on unrepresentative data, they may perform worse for under‑represented groups, exacerbating health inequities. Investing in robust data pipelines, curation, and governance – along with partnerships that broaden access to diverse datasets – is therefore critical.

At the same time, genomic and clinical data are among the most sensitive information a person can share. Compliance with privacy regulations (such as GDPR and HIPAA), strong de‑identification techniques, secure data environments and clear consent frameworks are non‑negotiable for maintaining trust.

2. Explainability and scientific validation

Many deep‑learning models function as black boxes, which is problematic in high‑stakes biological and clinical decisions. Regulators, clinicians and scientists need to understand not only whether a model works, but why. This is driving demand for explainable AI techniques, hybrid models that combine mechanistic knowledge with machine learning, and rigorous validation workflows.

In practice, AI‑generated hypotheses must still be validated experimentally and clinically. Closed‑loop systems that tightly couple model outputs with wet‑lab feedback can help, but organizations must resist the temptation to over‑trust in silico results without sufficient empirical evidence.

3. Regulatory and liability frameworks

Regulators are actively updating frameworks for AI‑enabled devices and software, and similar discussions are underway for AI‑discovered drugs and adaptive trial designs. Questions include: How should models be updated post‑approval? How are responsibilities shared between software developers, sponsors and healthcare providers? What level of documentation and monitoring is required?

Companies that engage early with regulators, participate in pilots or sandboxes, and build internal regulatory intelligence around AI will be better positioned than those that treat compliance as an afterthought.

4. Workforce and organizational change

AI will reshape scientific workflows but will not eliminate the need for human expertise. The most successful organizations are likely to be those that:

• Reskill scientists and clinicians to work effectively with AI tools.
• Build truly cross‑functional teams where machine‑learning experts, biologists, chemists, clinicians and product leaders collaborate.
• Align incentives so that AI augments – rather than threatens – professional identity and career paths.

5. Cybersecurity and model integrity

As AI becomes central to critical decisions, the models themselves and the data they consume become attractive attack surfaces. Threats range from theft of proprietary models and datasets to adversarial attacks that subtly manipulate inputs. Security‑by‑design, continuous monitoring and robust incident‑response plans should be part of any serious AI‑biotech strategy.